Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Targeting integrin (alpha)v(beta)3 in the treatment of malignant glioma

FY 2010-11

Summary
The most common form of brain cancer, glioblastoma multiforme (GBM), is highly aggressive, virtually untreatable and most often fatal. This is reflected in the median survival time of GBM patients which is in the range of 14 months with surgery and currently available treatments. Encouragingly, Cilengitide, a drug discovered over 15 years ago by my mentor David Cheresh in collaboration with scientists at Merck KGa, is showing promise in patients with this form of cancer. Cilengitide targets a cell adhesion receptor, integrin (alpha)v(beta)3, on the surface of these tumor cells. Importantly, Cilengitide has been significantly extending the lifespan of GBM patients in clinical trials. While some patients respond exceptionally well to this drug others fail to respond. Therefore I plan to study in detail how Cilengitide works at the molecular level. These studies should help us better understand why this drug works in some patients and identify ways of improving its activity in others. Recently I discovered that integrin (alpha)v(beta)3 activates c-Raf, another molecule implicated in GBM tumor cell survival and proliferation. As a result of these findings, I propose to delineate how integrin (alpha)v(beta)3 and c-Raf contribute to GBM tumor growth both in cellular and in animal models. In fact the Cheresh laboratory has already begun to develop a new class of Raf inhibitors that are effective in treating certain cancer types in mice. It is my hypothesis that by combining these c-Raf-targeted drugs and Cilengitide it will be possible to observe a more potent anti-tumor effect in a wider range of patients with GBM.
Program
CIHR Fellowship
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
214234
Name
Franovic Aleksandra
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Targeting integrin (alpha)v(beta)3 in the treatment of malignant glioma
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Allosteric Raf Inhibitors; C-Raf; Cell Proliferation/Death Assays; Cell Signaling / Tumorigenic Mechanisms; Cilengitide; Glioblastoma Multiforme; Host-Tumor Interactions; Immunohistochemistry; Integrin Alpha V Beta 3; Orthotopic Brain Tumors
Abstract
The most common form of brain cancer, glioblastoma multiforme (GBM), is highly aggressive, virtually untreatable and most often fatal. This is reflected in the median survival time of GBM patients which is in the range of 14 months with surgery and currently available treatments. Encouragingly, Cilengitide, a drug discovered over 15 years ago by my mentor David Cheresh in collaboration with scientists at Merck KGa, is showing promise in patients with this form of cancer. Cilengitide targets a cell adhesion receptor, integrin (alpha)v(beta)3, on the surface of these tumor cells. Importantly, Cilengitide has been significantly extending the lifespan of GBM patients in clinical trials. While some patients respond exceptionally well to this drug others fail to respond. Therefore I plan to study in detail how Cilengitide works at the molecular level. These studies should help us better understand why this drug works in some patients and identify ways of improving its activity in others. Recently I discovered that integrin (alpha)v(beta)3 activates c-Raf, another molecule implicated in GBM tumor cell survival and proliferation. As a result of these findings, I propose to delineate how integrin (alpha)v(beta)3 and c-Raf contribute to GBM tumor growth both in cellular and in animal models. In fact the Cheresh laboratory has already begun to develop a new class of Raf inhibitors that are effective in treating certain cancer types in mice. It is my hypothesis that by combining these c-Raf-targeted drugs and Cilengitide it will be possible to observe a more potent anti-tumor effect in a wider range of patients with GBM.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Franovic, Aleksandra
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Direct Payment - $150,000 Grant (2010-11) | Canada Spends